General condition and symptom burden during RUX treatment
TSS
ECOG performance status of patients showed a trend towards improvement after RUX treatment (16.5% of patients with ECOG 2–4 at baseline vs 12.7% at Month 36), with the proportion of patients with no restrictions (ECOG 0) increasing over time (29.9% at baseline vs 43.7% at Month 36). In 29.0% of patients, the ECOG performance status decreased, while it tended to be increased in 18.8% of patients at Month 36, as compared with baseline (When assessed by physicians, overall constitutional symptoms were present in 66.2% of patients at baseline, but only in 37.2% patients (Also, upon patient self-assessment via the internationally accepted MPN-SAF questionnaire, there was a significant and relevant reduction in the number of symptoms reported, as measured by the TSS: TSS improved by 5.2 points at Month 1 and was maximally reduced by 7.4 points at Month 3, after which the reduction lessened but remained significantly improved. In total, quality of life, as reported by patients, improved significantly (MPN-SAF TSS changes over time in comparison to baseline. MPN-SAF TSS difference is shown in comparison to baseline for total patient cohort and divided by subentity 